Sildenafil Citrate Tablet, Film Coated
Product Images NDC 43063-940

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 43063-940). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063940 Label (43063940)

43063940 Label (43063940)
This is a label of sildenafil citrate tablets of 100mg, with 10 tablets in each package. It is important to keep it out of reach of children. The table contains sildenafil citrate equivalent to 100mg of sildenafil, indicated for the treatment of erectile dysfunction. The tablets are marked with "88" and are blue, round and manufactured by b Pharmaceuticals Incorporated. It's expiring in December 2020, and LOT:H19A25. The patient should take the tablet(s) several times a day and should call the doctor if he/she experiences any side effects. The label also provides contact information if the patient wishes to report a side effect to the FDA.*
FDA Label Image

Chemical Structure

Chemical Structure
FDA Label Image

Figure 1

Figure 1
The text describes a graph showing systolic blood pressure (measured in mmHg) before and after taking a dose of either sildenafil 100mg or a placebo. The graph shows the blood pressure readings taken at various time points after taking the medication, ranging from 0 to 120 minutes. However, the formatting is poor and there is some missing information, so the description may not be completely accurate.*
FDA Label Image

Figure 2

Figure 2
The text appears to be a part of a chart or graph representing the changes in SBP (Systolic Blood Pressure) in mmHG. It shows the comparison between two groups taking different medications, Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg, at different time intervals post-dose (5, 6, and 7 hours). However, as there are numerous missing characters and special symbols, it is difficult to make an accurate interpretation.*
FDA Label Image

Figure 3

Figure 3
This appears to be a chart displaying the change in systolic blood pressure (SBP) measured in mmHG over time postdose (in hours) for two groups - one taking Doxazosin combined with a placebo and the other taking Doxazosin combined with Sildenafil 50 mg. The chart displays values ranging from 0 to 40 mmHG for SBP change and from 1 to 8 hours for time postdose.*
FDA Label Image

Figure 4

Figure 4
This text seems to be a chart comparing the effects of Doxazosin with Sildenafil 100 mg and Doxazosin with Placebo on an unknown variable over time after dosing. The unit of measurement is mmHg. No further information is available to provide a more accurate description.*
FDA Label Image

Figure 5

Figure 5
FDA Label Image

Figure 6 1

Figure 6 1
FDA Label Image

Figure 6 2

Figure 6 2
FDA Label Image

Figure 7

Figure 7
This data represents the percentage of patients who reported improvement in a clinical trial for sildenafil citrate compared to a placebo. The improvement percentages range from 100% down to 24%, with each percentage corresponding to a different dosage of sildenafil citrate - 25mg, 50mg, and 100mg. The total number of patients in each group is listed next to each dosage.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.